BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

26 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
23
Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.EBI
AMRI
34
Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.EBI
AMRI
22
The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.EBI
AMRI
11
The discovery of diazepinone-based 5-HT3 receptor partial agonists.EBI
AMRI
27
Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1.EBI
AMRI
33
4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.EBI
AMRI
46
Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity.EBI
AMRI
36
Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists.EBI
AMRI
17
5-Functionalized indazoles as glucocorticoid receptor agonists.EBI
AMRI
35
Heterobiaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part II.EBI
AMRI
43
Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.EBI
AMRI
30
Epiminocyclohepta[b]indole analogs as 5-HT6 antagonists.EBI
AMRI
19
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.EBI
AMRI
26
5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.EBI
AMRI
30
Tetrahydrocarboline analogs as MCH-1 antagonists.EBI
AMRI
24
Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.EBI
AMRI
39
Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.EBI
AMRI
18
Synthesis and SAR of heterocyclic carboxylic acid isosteres based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.EBI
AMRI
30
2,3-Diaminopyrazines as rho kinase inhibitors.EBI
AMRI
30
Synthesis and structure-activity relationship of substitutions at the C-1 position of Delta9-tetrahydrocannabinol.EBI
AMRI
2
Application of combinatorial biocatalysis for a unique ring expansion of dihydroxymethylzearalenone.EBI
AMRI
34
Synthesis and Biological Evaluation of N-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1.EBI
AMRI
3
Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1EBI
AMRI
5
Bruton's Tyrosine Kinase Inhibitors for the Treatment of Autoimmune Diseases and Cancers.EBI
AMRI
12
New Substituted Cyanoindoline Derivatives as MAP3K14 Kinase Inhibitors for the Treatment of Cancer and Autoimmune Disorders.EBI
AMRI
9
Modulating GluN2B for the Treatment of Neurological and Psychiatric Disorders.EBI
AMRI